Related references
Note: Only part of the references are listed.Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease - a real-world two-center cohort study
Mohamed Attauabi et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2021)
Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study
Carl Eriksson et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)
Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study ICC Registry - Vedolizumab
Vince B. C. Biemans et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Exclusion rates in randomized controlled trials of treatments for physical conditions: a systematic review
Jinzhang He et al.
TRIALS (2020)
Long-term safety of vedolizumab for inflammatory bowel disease
Edward V. Loftus et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center
Gabriele Dragoni et al.
JOURNAL OF DIGESTIVE DISEASES (2019)
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study
Aurelien Amiot et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort
Lydia C. T. Buer et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2019)
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease
Sebastian Zeissig et al.
GUT (2019)
Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis
Tal Engel et al.
JOURNAL OF CROHNS & COLITIS (2018)
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Neeraj Narula et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety
Britt Christensen et al.
INFLAMMATORY BOWEL DISEASES (2018)
Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease
Stefan Schreiber et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry
Maria Chaparro et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial
B. G. Feagan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience
Uri Kopylov et al.
INFLAMMATORY BOWEL DISEASES (2017)
Systemic Chemokine Levels with Gut-Specific Vedolizumab in Patients with Inflammatory Bowel DiseaseA Pilot Study
Stephanie Zwicker et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
Fernando Magro et al.
JOURNAL OF CROHNS & COLITIS (2017)
One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study
A. Amiot et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study
D. C. Baumgart et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
A. Stallmach et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium
Parambir S. Dulai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
Aurelien Amiot et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort
Edward Shelton et al.
INFLAMMATORY BOWEL DISEASES (2015)
Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease
Mark T. Osterman et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
Bruce E. Sands et al.
GASTROENTEROLOGY (2014)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population
Christina Ha et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Short health scale: A valid, reliable, and responsive instrument for subjective health assessment in Crohn's disease
Henrik Stjernman et al.
INFLAMMATORY BOWEL DISEASES (2008)
Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis
James D. Lewis et al.
INFLAMMATORY BOWEL DISEASES (2008)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
Erik von Elm et al.
LANCET (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
